Circulation:抑制PI3Kγ可预防蒽环类药物的心毒性,同时可减缓肿瘤生长

2018-08-17 MedSci MedSci原创

蒽环类药物,如阿霉素(DOX),是有效抗癌(实体肿瘤和血液恶性肿瘤)药物。但是,其临床应用受到心脏毒性的限制。现有研究人员对磷酸肌醇3激酶γ(PI3Kγ)在DOX诱导的心脏毒性中的作用,以及PI3Kγ抑制剂潜在的心脏保护和抗癌作用进行研究。用DOX长期处理表达PI3Kγ或接受PI3Kγ选择性抑制剂处的小鼠。用心脏超声分析心功能,并评估整个心脏或分离的心肌的DOX介导的信号。在小鼠乳腺癌模型中评估P

蒽环类药物,如阿霉素(DOX),是有效抗癌(实体肿瘤和血液恶性肿瘤)药物。但是,其临床应用受到心脏毒性的限制。现有研究人员对磷酸肌醇3激酶γ(PI3Kγ)在DOX诱导的心脏毒性中的作用,以及PI3Kγ抑制剂潜在的心脏保护和抗癌作用进行研究。

用DOX长期处理表达PI3Kγ或接受PI3Kγ选择性抑制剂处的小鼠。用心脏超声分析心功能,并评估整个心脏或分离的心肌的DOX介导的信号。在小鼠乳腺癌模型中评估PI3Kγ抑制剂的心脏保护和抗肿瘤效应。

PI3Kγ激酶抑制的小鼠在长期小剂量DOX处理后心脏功能未受损,提示其可抵抗DOX诱导的心毒性。PI3Kγ抑制剂的有利效应主要是通过增强DOX破坏的线粒体自噬清除来实现的。与之相一致,药物或遗传阻断体内的自噬清除即可破坏PI3Kγ激酶抑制小鼠对DOX心毒性的抵抗力。机制上,在DOX处理的心脏中,Toll样受体9的下游,PI3Kγ被损伤的细胞器所释放的和自噬体所吞噬的线粒体DNA激活。自噬体PI3Kγ/Akt/mTor/UIK1信号通过不良适应反馈抑制自噬。在乳腺癌模型中阻断PI3Kγ可预防DOX诱导的心功能不全,同时,通过释放抗癌免疫增强DOX的抗肿瘤活性。

在抗癌治疗中,封闭PI3Kγ或可发挥双重治疗效应,即预防蒽环类药物的心毒性和减缓肿瘤生长。

原始出处:



本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1333202, encodeId=00ba133320293, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418118, encodeId=db66141811888, content=<a href='/topic/show?id=3caf8834200' target=_blank style='color:#2F92EE;'>#蒽环类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88342, encryptionId=3caf8834200, topicName=蒽环类药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ab3331025, createdName=cy0325, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521703, encodeId=ba671521e03f7, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339326, encodeId=0172339326ef, content=不错耶,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:19:01 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339274, encodeId=b9523392e434, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 18 08:59:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339154, encodeId=a2e0339154dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Aug 17 17:07:40 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1333202, encodeId=00ba133320293, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418118, encodeId=db66141811888, content=<a href='/topic/show?id=3caf8834200' target=_blank style='color:#2F92EE;'>#蒽环类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88342, encryptionId=3caf8834200, topicName=蒽环类药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ab3331025, createdName=cy0325, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521703, encodeId=ba671521e03f7, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339326, encodeId=0172339326ef, content=不错耶,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:19:01 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339274, encodeId=b9523392e434, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 18 08:59:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339154, encodeId=a2e0339154dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Aug 17 17:07:40 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1333202, encodeId=00ba133320293, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418118, encodeId=db66141811888, content=<a href='/topic/show?id=3caf8834200' target=_blank style='color:#2F92EE;'>#蒽环类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88342, encryptionId=3caf8834200, topicName=蒽环类药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ab3331025, createdName=cy0325, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521703, encodeId=ba671521e03f7, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339326, encodeId=0172339326ef, content=不错耶,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:19:01 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339274, encodeId=b9523392e434, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 18 08:59:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339154, encodeId=a2e0339154dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Aug 17 17:07:40 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1333202, encodeId=00ba133320293, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418118, encodeId=db66141811888, content=<a href='/topic/show?id=3caf8834200' target=_blank style='color:#2F92EE;'>#蒽环类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88342, encryptionId=3caf8834200, topicName=蒽环类药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ab3331025, createdName=cy0325, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521703, encodeId=ba671521e03f7, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339326, encodeId=0172339326ef, content=不错耶,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:19:01 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339274, encodeId=b9523392e434, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 18 08:59:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339154, encodeId=a2e0339154dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Aug 17 17:07:40 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
    2018-08-18 owlhealth

    不错耶,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1333202, encodeId=00ba133320293, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418118, encodeId=db66141811888, content=<a href='/topic/show?id=3caf8834200' target=_blank style='color:#2F92EE;'>#蒽环类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88342, encryptionId=3caf8834200, topicName=蒽环类药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ab3331025, createdName=cy0325, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521703, encodeId=ba671521e03f7, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339326, encodeId=0172339326ef, content=不错耶,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:19:01 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339274, encodeId=b9523392e434, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 18 08:59:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339154, encodeId=a2e0339154dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Aug 17 17:07:40 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
    2018-08-18 kafei

    学习学习谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1333202, encodeId=00ba133320293, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418118, encodeId=db66141811888, content=<a href='/topic/show?id=3caf8834200' target=_blank style='color:#2F92EE;'>#蒽环类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88342, encryptionId=3caf8834200, topicName=蒽环类药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ab3331025, createdName=cy0325, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521703, encodeId=ba671521e03f7, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Sun Aug 19 07:52:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339326, encodeId=0172339326ef, content=不错耶,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:19:01 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339274, encodeId=b9523392e434, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 18 08:59:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339154, encodeId=a2e0339154dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Aug 17 17:07:40 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
    2018-08-17 happsf

    学习

    0

相关资讯

JCO:“砒霜”可减少急性早幼粒细胞白血病中蒽环类药物剂量

众所周知三氧化二砷(ATO)已成为白血病治疗的有效成分。近日在JCO上发表的一篇文章则通过新诊断的儿童急性早幼粒细胞白血病(APL)儿童肿瘤学组AAML0631试验的一项III期历史对照试验,来确定接受ATO巩固和减少剂量蒽环类药物治疗的患者的生存率。

Ann Onco:FOXP3表达示蒽环类抗乳腺癌效果

  法国学者3月19日在线发表于《肿瘤学年鉴》(Annals of Oncology)的一项研究表明,乳腺癌细胞POXP3表达状态可能可以精确预测蒽环类抗乳腺癌效果。   该研究显示,乳腺癌细胞表达FOXP3与较好的总生存(OS)状况相关(P=0.003)。   单变量和多变量分析显示,乳腺癌细胞表达FOXP3与接受蒽环类为基础辅助化疗而非蒽环类-紫杉烷序贯化疗的患者较好的OS状态具有独立相关

JNCI:蒽环类与曲妥珠单抗带来心脏衰竭风险

    临床试验结果已经显示,乳腺癌患者接受蒽环类和曲妥珠单抗(赫赛汀,罗氏)的治疗会增加心力衰竭和心肌病的风险。但是在临床试验之外的患者人群中,治疗与风险的关系是怎样?一项研究结果表明:在“现实世界”的观察性队列研究能够表明这样的风险可能会更高。该研究发表于8月31日美国国家癌症研究所杂志。     中位随访时间比之前的临床试验延长了

Int J Cardiol:蒽环类和曲妥珠单抗治疗乳腺癌后心脏效应的晚期特征!

由此可见,使用先进的CMR,当代化疗方案表现出最小的长期心脏毒性。这项研究表明这些患者在化疗12个月后应限制系列成像检查。

JAHA:接受蒽环类化疗的儿童和年轻成人心脏毒性的潜在标志物

在这个研究中,ACs治疗后会出现心脏相关的血浆miRNA失调。AC治疗后血浆中miR-29b和miR-499会急性升高,并可以观察到蒽环类药物剂量和心肌损伤标志物存在量效关系。进一步评估miRNAs可能为AC诱导的心脏毒性的机制提供了新视角,并得到通过早期干预来减轻心脏毒性的生物标志物。

蒽环类药物心脏毒性防治共识

蒽环类药物心脏毒性防治共识